4-1BB is a target for immunotherapy in patients with undifferentiated pleomorphic sarcoma
Miriam J Melake; Henry G Smith; David Mansfield; Emma Davies; Magnus T Dillon; Anna C Wilkins; Emmanuel C Patin; Malin Pedersen; Richard Buus; Aisha B Miah; Shane H Zaidi; Khin Thway; Alan A Melcher; Andrew J Hayes; Tim R Fenton; Kevin J Harrington; Martin McLaughlin
Show abstract
Systemic relapse, after treatment of a localised primary tumour with neo-adjuvant radiotherapy and surgery, is the major cause of disease related mortality in patients with sarcoma. As with other cancers, many sarcoma patients derive no benefit from anti-PD-1 treatment. Combining radiotherapy and immunotherapy is under investigation as a means to improve response rates and control metastatic disease. Here, we use a retrospective cohort of sarcoma patients, treated with neoadjuvant radiotherapy, and TCGA data to explore patient stratification for immunotherapy and therapeutic targets of relevance to sarcoma. We show a group of patients with immune-hot undifferentiated pleomorphic sarcoma as one of the highest-ranking candidates for emerging 4-1BB targeting agents. A binary hot/cold classification method indicates 4-1BB-high hot sarcomas share many characteristics with immunotherapy responsive cancers of other pathologies. Hot tumours in sarcoma are however substantially less prevalent. Patient stratification, of intense interest for immunotherapies, is therefore even more important in sarcoma.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Multimodal profiling of chordoma immunity reveals distinct immune contextures 97%
- Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+ T cells in the tumor microenvironment and predicts clinical outcome in early- and late-phase clinical trials 95%
- Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T cell receptor signalling. 95%
Similar papers in this journal
- Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study 95%
- Multiparametric MRI Along with Machine Learning Predicts Prognosis and Treatment Response in Pediatric Low-Grade Glioma 95%
- Predicting immunotherapy response in advanced bladder cancer: a meta-analysis of six independent cohorts 95%
Similar papers in this journal
- Single-Cell Spatial Proteomics Analyses of Head and Neck Squamous Cell Carcinoma Reveal Tumor Heterogeneity and Immune Architectures Associated with Clinical Outcome 95%
- Genetic and Epigenetic Characterization of Sarcoma Stem Cells Across Subtypes Identifies EZH2 as a Therapeutic Target 95%
- Development and validation of a gene expression score to account for tumour purity and improve prognostication in breast cancer 93%
Similar papers in this journal
- Tumor-localized interleukin-2 and interleukin-12 combine with radiation therapy to safely potentiate regression of advanced malignant melanoma in pet dogs 94%
- High-dimensional and spatial analysis reveals immune landscape dependent progression in cutaneous squamous cell carcinoma 93%
- Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer 93%
Similar papers in this journal
- A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma 94%
- Comprehensive analysis of mutational signatures in pediatric cancers 93%
- Cancer-associated fibroblast compositions change with breast cancer progression linking S100A4 and PDPN ratios with clinical outcome 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.